158 related articles for article (PubMed ID: 8540360)
1. Site-directed mutagenesis of HIV-1 protease: generation of mutant proteases with increased stability to autodigestion.
Tomasselli AG; Mildner AM; Rothrock DJ; Sarcich JL; Lull J; Leone J; Heinrikson R
Adv Exp Med Biol; 1995; 362():473-7. PubMed ID: 8540360
[No Abstract] [Full Text] [Related]
2. Cloning, isolation, expression and mutagenesis studies on the human immuno-deficiency virus type 1 (HIV-1) protease.
Garner JC; Shoolingin-Jordan PM
Biochem Soc Trans; 1998 Aug; 26(3):S287. PubMed ID: 9766006
[No Abstract] [Full Text] [Related]
3. Identification of amino acid residues of the retroviral aspartic proteinases important for substrate specificity and catalytic efficiency.
Cameron CE; Burstein H; Bizub-Bender D; Ridky T; Weber IT; Wlodawer A; Skalka AM; Leis J
Adv Exp Med Biol; 1995; 362():399-406. PubMed ID: 8540349
[No Abstract] [Full Text] [Related]
4. [HIV-1 proteinase mutant with an altered region of the active center].
Dergousova NI; Rumsh LD; Andreeva NS
Mol Biol (Mosk); 1998; 32(4):678-85. PubMed ID: 9785574
[No Abstract] [Full Text] [Related]
5. Proteolysis of an active site peptide of lactate dehydrogenase by human immunodeficiency virus type 1 protease.
Tomaszek TA; Moore ML; Strickler JE; Sanchez RL; Dixon JS; Metcalf BW; Hassell A; Dreyer GB; Brooks I; Debouck C
Biochemistry; 1992 Oct; 31(42):10153-68. PubMed ID: 1420138
[TBL] [Abstract][Full Text] [Related]
6. Autoprocessing of the HIV-1 protease using purified wild-type and mutated fusion proteins expressed at high levels in Escherichia coli.
Louis JM; McDonald RA; Nashed NT; Wondrak EM; Jerina DM; Oroszlan S; Mora PT
Eur J Biochem; 1991 Jul; 199(2):361-9. PubMed ID: 2070793
[TBL] [Abstract][Full Text] [Related]
7. Mutants of HIV-1 protease with enhanced stability to autodegradation.
Tomasselli AG; Mildner AM; Rothrock DJ; Sarcich JL; Lull J; Leone J; Heinrikson RL
Adv Exp Med Biol; 1995; 362():387-98. PubMed ID: 8540348
[No Abstract] [Full Text] [Related]
8. Solution NMR evidence that the HIV-1 protease catalytic aspartyl groups have different ionization states in the complex formed with the asymmetric drug KNI-272.
Wang YX; Freedberg DI; Yamazaki T; Wingfield PT; Stahl SJ; Kaufman JD; Kiso Y; Torchia DA
Biochemistry; 1996 Aug; 35(31):9945-50. PubMed ID: 8756455
[TBL] [Abstract][Full Text] [Related]
9. A side chain at position 48 of the human immunodeficiency virus type-1 protease flap provides an additional specificity determinant.
Moody MD; Pettit SC; Shao W; Everitt L; Loeb DD; Hutchison CA; Swanstrom R
Virology; 1995 Mar; 207(2):475-85. PubMed ID: 7886951
[TBL] [Abstract][Full Text] [Related]
10. Conformational stability and catalytic activity of HIV-1 protease are both enhanced at high salt concentration.
Szeltner Z; Polgár L
J Biol Chem; 1996 Mar; 271(10):5458-63. PubMed ID: 8621402
[TBL] [Abstract][Full Text] [Related]
11. Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors.
Maschera B; Furfine E; Blair ED
J Virol; 1995 Sep; 69(9):5431-6. PubMed ID: 7636988
[TBL] [Abstract][Full Text] [Related]
12. Crystal structure of human immunodeficiency virus (HIV) type 2 protease in complex with a reduced amide inhibitor and comparison with HIV-1 protease structures.
Tong L; Pav S; Pargellis C; Dô F; Lamarre D; Anderson PC
Proc Natl Acad Sci U S A; 1993 Sep; 90(18):8387-91. PubMed ID: 8378311
[TBL] [Abstract][Full Text] [Related]
13. The HIV-1 protease as enzyme and substrate: mutagenesis of autolysis sites and generation of a stable mutant with retained kinetic properties.
Mildner AM; Rothrock DJ; Leone JW; Bannow CA; Lull JM; Reardon IM; Sarcich JL; Howe WJ; Tomich CS; Smith CW
Biochemistry; 1994 Aug; 33(32):9405-13. PubMed ID: 8068616
[TBL] [Abstract][Full Text] [Related]
14. Human immunodeficiency virus type 1 and type 2 protease monomers are functionally interchangeable in the dimeric enzymes.
Patterson CE; Seetharam R; Kettner CA; Cheng YS
J Virol; 1992 Feb; 66(2):1228-31. PubMed ID: 1731102
[TBL] [Abstract][Full Text] [Related]
15. Interaction of mutant forms of the HIV-1 protease with substrate and inhibitors.
Darke PL; Kohl NE; Hanobik MG; Leu CT; Vacca JP; Guare JP; Heimbach JC; Dixon RA
Adv Exp Med Biol; 1991; 306():483-7. PubMed ID: 1812746
[No Abstract] [Full Text] [Related]
16. HIV protease: a novel chemotherapeutic target for AIDS.
Huff JR
J Med Chem; 1991 Aug; 34(8):2305-14. PubMed ID: 1875332
[No Abstract] [Full Text] [Related]
17. Expression, characterisation and mutagenesis of the aspartic proteinase from equine infectious anaemia virus.
Powell DJ; Bur D; Wlodawer A; Gustchina A; Payne SL; Dunn BM; Kay J
Eur J Biochem; 1996 Oct; 241(2):664-74. PubMed ID: 8917470
[TBL] [Abstract][Full Text] [Related]
18. Purification and characterization of naturally occurring HIV-1 (South African subtype C) protease mutants from inclusion bodies.
Maseko SB; Natarajan S; Sharma V; Bhattacharyya N; Govender T; Sayed Y; Maguire GE; Lin J; Kruger HG
Protein Expr Purif; 2016 Jun; 122():90-6. PubMed ID: 26917227
[TBL] [Abstract][Full Text] [Related]
19. Site-directed mutagenesis of a disulfide bridge in cathepsin D: expression, activation, purification, and characterization.
Beyer BM; Dunn BM
Adv Exp Med Biol; 1995; 362():285-7. PubMed ID: 8540329
[No Abstract] [Full Text] [Related]
20. Regulation of autoproteolysis of the HIV-1 and HIV-2 proteases with engineered amino acid substitutions.
Rosé JR; Salto R; Craik CS
J Biol Chem; 1993 Jun; 268(16):11939-45. PubMed ID: 8505318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
